Division of Pharmaceutics and Pharmacology, College of Pharmacy & Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Molecules. 2021 Sep 10;26(18):5500. doi: 10.3390/molecules26185500.
Membrane transporters play an important role in the absorption, distribution, metabolism, and excretion of xenobiotic substrates, as well as endogenous compounds. The evaluation of transporter-mediated drug-drug interactions (DDIs) is an important consideration during the drug development process and can guide the safe use of polypharmacy regimens in clinical practice. In recent years, several endogenous substrates of drug transporters have been identified as potential biomarkers for predicting changes in drug transport function and the potential for DDIs associated with drug candidates in early phases of drug development. These biomarker-driven investigations have been applied in both preclinical and clinical studies and proposed as a predictive strategy that can be supplanted in order to conduct prospective DDIs trials. Here we provide an overview of this rapidly emerging field, with particular emphasis on endogenous biomarkers recently proposed for clinically relevant uptake transporters.
膜转运蛋白在异生物质底物以及内源性化合物的吸收、分布、代谢和排泄中起着重要作用。评估转运蛋白介导的药物-药物相互作用(DDI)是药物开发过程中的一个重要考虑因素,并能指导临床实践中多药治疗方案的安全使用。近年来,一些药物转运蛋白的内源性底物已被确定为预测药物转运功能变化的潜在生物标志物,以及与药物候选物相关的 DDI 潜力,这些潜在生物标志物在药物开发的早期阶段得到了应用。这些基于生物标志物的研究已经在临床前和临床研究中得到了应用,并被提出作为一种预测策略,可以取代进行前瞻性 DDI 试验。本文概述了这一快速发展的领域,特别强调了最近提出的与临床相关摄取转运蛋白有关的内源性生物标志物。